Targets › DHFR
34 programs from 28 companies in 47 trials: 22 Phase 2, 11 Phase 3, 11 Phase 1, 3 Phase 4; Oncology, Infectious disease, Immunology; next expected readout Dec 2026.
Catalyzes the reduction of 7,8-dihydrofolate (DHF) to 5,6,7,8-tetrahydrofolate in a NADPH-dependent manner. Key enzyme in folate metabolism. (UniProt, P00374)
Open in Phaseline: the race on DHFR, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Tongji Hospital | Trimethoprim Bacterial dihydrofolate reductase inhibitor | DHFR, DHPS | Phase 4 | Pneumonia, Pneumocystis | Dec 2026 |
| Indiana University | Trimethoprim-sulfamethoxazole (TMP-SMX) Dihydropteroate synthase and dihydrofolate reductase inhibitor; inhibits bacterial folate | DHPS, DHFR | Phase 4 | Methicillin Resistant Staphylococcus Aureus | Jun 2027 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Pyrimethamine Dihydrofolate reductase inhibitor | DHFR | Phase 4 | Toxoplasmosis | Dec 2030 |
| Kyungpook National University Hospital | FOLFOX-6 Combination chemotherapy: oxaliplatin (platinum agent), leucovorin (reduced folate), and 5 | DPYD, TYMS, DHFR | Phase 3 | Colon Cancer | Dec 2026 |
| Acrotech Biopharma | Pralatrexate Dihydrofolate reductase inhibitor | DHFR | Phase 3 | Peripheral T Cell Lymphoma; Advanced Solid Tumors; Lymphoma, T-Cell; PTCL … | Feb 2027 |
| Centre Hospitalier Universitaire Dijon | modified FOLFOX Multi-drug chemotherapy: folate antagonist (folinic acid), thymidylate synthase inhibitor | TOPO2, TYMS, DHFR, SLC22A16 | Phase 3 | Colon Cancer; Locally Advanced or Metastatic Small Bowel Adenocarcinoma | Feb 2027 |
| Seoul National University Hospital | mFOLFIRINOX (preoperative) Multi-agent chemotherapy combining irinotecan (topoisomerase I inhibitor), fluorouracil (t | TOPO1, DHFR, TYMS | Phase 3 | Resectable Pancreatic Cancer | Dec 2027 |
| Tampere University | Sulfadoxine Dihydropteroate synthetase inhibitor | DHPS, DHFR | Phase 3 | Malaria | Dec 2027 |
| Fudan University | XELOX adjuvant chemotherapy Multi-agent chemotherapy: oxaliplatin (platinum agent) and capecitabine (5-fluorouracil pr | DHFR, TYMS, SLC22A16 | Phase 3 | High-risk Stage II Colorectal Cancer | Jun 2028 |
| Fudan University | mFOLFIRINOX adjuvant chemotherapy Multi-agent chemotherapy: oxaliplatin (platinum agent), irinotecan (topoisomerase I inhibi | DHFR, TYMS, TOPO1, SLC22A16 | Phase 3 | High-risk Stage II Colorectal Cancer | Jun 2028 |
| Fudan University | mFOLFOX6 adjuvant chemotherapy Multi-agent chemotherapy: oxaliplatin (platinum agent), leucovorin (folinic acid), and 5-f | DHFR, TYMS, SLC22A16 | Phase 3 | High-risk Stage II Colorectal Cancer | Jun 2028 |
| Kyungpook National University Hospital | FOLFOX Combination chemotherapy: 5-fluorouracil + leucovorin + oxaliplatin | DHFR, TYMS | Phase 3 | Colon Cancer | Dec 2028 |
| Sixth Affiliated Hospital, Sun Yat-sen University | CapeOx chemotherapy regimen Capecitabine/oxaliplatin combination chemotherapy | TYMS, DHFR | Phase 3 | Colorectal Cancer | Feb 2031 |
| Sixth Affiliated Hospital, Sun Yat-sen University | FOLFOX chemotherapy regimen 5-FU/leucovorin/oxaliplatin combination chemotherapy | TYMS, DHFR | Phase 3 | Colorectal Cancer | Feb 2031 |
| Ruijin Hospital | S-1 Oral fluoropyrimidine (tegafur/5-FU/gimeracil/oteracil combination) | TYMS, DHFR | Phase 2 | Pancreatic Neoplasms; Gastric or Esophagogastric Junction Adenocarcinoma | Dec 2026 |
| National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Trimethoprim Bacterial dihydrofolate reductase inhibitor | DHFR | Phase 2 | Eczema | Jan 2027 |
| Rutgers, The State University of New Jersey | sFOLFOXIRI (alternating FOLFOX and FOLFIRI) Fluorouracil-based chemotherapy combining FOLFOX (5-fluorouracil, leucovorin, oxaliplatin) | DHFR, TYMS, TOPO1 | Phase 2 | Gastro-Intestinal Cancer | Feb 2027 |
| Lithuanian University of Health Sciences | FOLFOX4 Combination chemotherapy with oxaliplatin (platinum agent), 5-fluorouracil (thymidylate sy | DHFR, TYMS | Phase 2 | Neoadjuvant Therapy in Rectal Cancer, Radiotherapy, FOLFOX | Jun 2027 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | S-1 Fluoropyrimidine combination (5-FU prodrug with CDHP and OXO) | TYMS, DHFR | Phase 2 | Gastric Cancer | Jul 2027 |
| Tianjin Medical University Cancer Institute and Hospital | Leucovorin (LV) Reduced folate cofactor enhancing 5-FU activity | DHFR | Phase 2 | Colorectal Cancer (CRC) | Aug 2027 |
| Qingdao Central Hospital | TAS-102 5-FU prodrug with thymidylate synthase and dihydrofolate reductase inhibition | TYMS, DHFR | Phase 2 | EFS | Dec 2027 |
| Mayo Clinic | Pemetrexed Disodium Thymidylate synthase inhibitor; Dihydrofolate reductase inhibitor; GAR transformylase inhibitor | TYMS, DHFR, GART | Phase 2 | Metastatic Salivary Gland Carcinoma | Feb 2028 |
| Fudan University | mFOLFIRINOX plus IMRT Multi-drug chemotherapy regimen (5-fluorouracil, folinic acid, irinotecan, oxaliplatin) co | TOPO1, DPYD, TYMS, DHFR | Phase 2 | Pancreatic Adenocarcinoma; Pancreatic Cancer | Mar 2028 |
| Dartmouth-Hitchcock Medical Center | modified FOLFIRINOX (mFOLFIRINOX) Combination of 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin; multi-targeted che | TYMS, DHFR | Phase 2 | Pancreas Adenocarcinoma | Jul 2028 |
| Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Tegafur Antimetabolite (prodrug of fluorouracil) | TYMS, DHFR | Phase 2 | Immunotherapy | Sep 2028 |
| UNICANCER | Lonsurf (Trifluridine/tipiracil) Thymidylate synthase inhibitor and DHFR inhibitor combination; trifluridine is a nucleosid | TYMS, DHFR | Phase 2 | Metastatic Colorectal Cancer | Oct 2028 |
| NRG Oncology | Pemetrexed Disodium Thymidylate synthase inhibitor; Dihydrofolate reductase inhibitor; GAR transformylase inhibitor | TYMS, DHFR, GART | Phase 2 | Recurrent Non-Small Cell Lung Carcinoma | Dec 2028 |
| Centre Georges Francois Leclerc | FOLFIRINOX3 Combination chemotherapy: 5-FU (thymidylate synthase inhibitor), irinotecan (topoisomerase | TYMS, DHFR | Phase 2 | Metastatic Pancreatic Cancer | Jul 2029 |
| Duke University | FLOT 5-FU + Leucovorin + Oxaliplatin + Docetaxel (antimetabolite + folinic acid + platinum alky | TYMS, DHFR | Phase 2 | Esophageal Adenocarcinoma | Sep 2029 |
| Duke University | Modified-FOLFOX-6 5-FU + Leucovorin + Oxaliplatin (5-FU thymidylate synthase inhibitor + folinic acid + plat | TYMS, DHFR | Phase 2 | Esophageal Adenocarcinoma | Sep 2029 |
| Ashish Shah | DB107-FC Flucytosine; prodrug converted by cytosine deaminase to fluorouracil | TYMS, DHFR | Phase 2 | High Grade Glioma | May 2034 |
| Clinica Universidad de Navarra, Universidad de Navarra | TTFields Combination chemotherapy: folate antagonist (5-FU/leucovorin), topoisomerase I inhibitor ( | TYMS, DHFR | Phase 1 | Pancreatic Adenocarcinoma Metastatic | Mar 2027 |
| National Cancer Institute (NCI) | Pemetrexed Disodium Thymidylate synthase inhibitor; Dihydrofolate reductase inhibitor; GAR transformylase inhibitor | TYMS, DHFR, GART | Phase 1 | Epithelioid Mesothelioma; Biphasic Mesothelioma | Mar 2027 |
| University of Texas Southwestern Medical Center | Leucovorin Folinic acid; enhances 5-fluorouracil activity | DHFR | Phase 1 | Gastro-esophageal Junction (GEJ) Cancer | Oct 2027 |
Colon Cancer (3) High-risk Stage II Colorectal Cancer (3) Colorectal Cancer (2) Gastric Cancer (2) Esophageal Adenocarcinoma (2) Pancreatic Adenocarcinoma Metastatic (2) EFS (2) Malaria (1) Neoadjuvant Therapy in Rectal Cancer, Radiotherapy, FOLFOX (1) Pancreas Adenocarcinoma (1) Locally Advanced or Metastatic Small Bowel Adenocarcinoma (1) Colorectal Cancer (CRC) (1)
small molecule (24), mixed (4), antibody (1)
Fudan University (4) Sixth Affiliated Hospital, Sun Yat-sen University (2) Duke University (2) Kyungpook National University Hospital (2) Tampere University (1) Lithuanian University of Health Sciences (1) Dartmouth-Hitchcock Medical Center (1) Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1) Centre Hospitalier Universitaire Dijon (1) Tianjin Medical University Cancer Institute and Hospital (1) Ashish Shah (1) NRG Oncology (1) UNICANCER (1) Rutgers, The State University of New Jersey (1) Centre Georges Francois Leclerc (1) Tongji Hospital (1) Daping Hospital and the Research Institute of Surgery of the Third Military Medical University (1) University of Texas Southwestern Medical Center (1) Acrotech Biopharma (1) National Cancer Institute (NCI) (1)
TYMS (26) SLC22A16 (4) TOPO1 (4) DHPS (3) GART (3) DPYD (2) TOPO2 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.